• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测 COVID-19 患者发生医院获得性感染的因素和结果。

Predictors and outcomes of healthcare-associated infections in COVID-19 patients.

机构信息

Department of Pulmonary & Critical Care, Northeast Georgia Health System, Gainesville, GA, USA.

Department of Internal Medicine, Northeast Georgia Health System, Gainesville, GA, USA.

出版信息

Int J Infect Dis. 2021 Mar;104:287-292. doi: 10.1016/j.ijid.2020.11.135. Epub 2020 Nov 15.

DOI:10.1016/j.ijid.2020.11.135
PMID:33207271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7666872/
Abstract

INTRODUCTION

Healthcare-associated infections (HAI) after viral illnesses are important sources of morbidity and mortality. This has not been extensively studied in hospitalized COVID-19 patients.

METHODS

This study included all COVID-19-positive adult patients (≥18 years) hospitalized between 01 March and 05 August 2020 at the current institution. The Centers for Disease Control and Prevention definition of HAI in the acute care setting was used. The outcomes that were studied were rates and types of infections and in-hospital mortality. Several multivariable logistic regression models were constructed to examine characteristics associated with development of HAI.

RESULTS

Fifty-nine (3.7%) of 1565 patients developed 140 separate HAIs from 73 different organisms: 23 were Gram-positive, 39 were Gram-negative and 11 were fungal. Patients who developed HAI did not have higher odds of death (OR 0.85, 95% CI 0.40-1.81, p =  0.69). HAIs were associated with the use of tocilizumab (OR 5.04, 95% CI 2.4-10.6, p <  0.001), steroids (OR 3.8, 95% CI 1.4-10, p =  0.007), hydroxychloroquine (OR 3.0, 95% CI 1.0-8.8, p =  0.05), and acute kidney injury requiring hemodialysis (OR 3.7, 95% CI 1.1-12.8, p =  0.04).

CONCLUSIONS

HAI were common in hospitalized Covid-19 patients. Tocilizumab and steroids were associated with increased risk of HAIs.

摘要

引言

病毒性疾病后发生的医源性感染(HAI)是发病率和死亡率的重要来源。但这在住院的 COVID-19 患者中尚未得到广泛研究。

方法

本研究纳入了 2020 年 3 月 1 日至 8 月 5 日期间,在本机构住院的所有(≥18 岁)COVID-19 阳性成年患者。采用美国疾病控制与预防中心在急性护理环境中对 HAI 的定义。研究的结局是感染率和类型以及住院死亡率。构建了几个多变量逻辑回归模型,以检查与 HAI 发生相关的特征。

结果

在 1565 名患者中,有 59 名(3.7%)患者发生了 140 例由 73 种不同病原体引起的单独 HAI:23 例为革兰氏阳性菌,39 例为革兰氏阴性菌,11 例为真菌。发生 HAI 的患者死亡的几率没有更高(比值比 0.85,95%置信区间 0.40-1.81,p=0.69)。HAI 与托珠单抗(比值比 5.04,95%置信区间 2.4-10.6,p<0.001)、皮质类固醇(比值比 3.8,95%置信区间 1.4-10,p=0.007)、羟氯喹(比值比 3.0,95%置信区间 1.0-8.8,p=0.05)和需要血液透析的急性肾损伤(比值比 3.7,95%置信区间 1.1-12.8,p=0.04)的使用有关。

结论

在住院的 COVID-19 患者中,HAI 很常见。托珠单抗和皮质类固醇与 HAI 风险增加有关。

相似文献

1
Predictors and outcomes of healthcare-associated infections in COVID-19 patients.预测 COVID-19 患者发生医院获得性感染的因素和结果。
Int J Infect Dis. 2021 Mar;104:287-292. doi: 10.1016/j.ijid.2020.11.135. Epub 2020 Nov 15.
2
The impact of the COVID-19 pandemic on healthcare-associated infections in intensive care unit patients: a retrospective cohort study.2019冠状病毒病大流行对重症监护病房患者医疗相关感染的影响:一项回顾性队列研究。
Antimicrob Resist Infect Control. 2021 Jun 4;10(1):87. doi: 10.1186/s13756-021-00959-y.
3
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.托珠单抗和皮质类固醇治疗 COVID-19 肺炎患者。
PLoS One. 2020 Aug 20;15(8):e0237831. doi: 10.1371/journal.pone.0237831. eCollection 2020.
4
Clinical and microbiological profile of health care-associated infections in a tertiary hospital: Comparison between a cohort of hospitalized patients during prepandemic and COVID-19 pandemic periods.三级医院医源性感染的临床和微生物学特征:大流行前和 COVID-19 大流行期间住院患者队列的比较。
Am J Infect Control. 2024 Jun;52(6):712-718. doi: 10.1016/j.ajic.2023.12.018. Epub 2024 Jan 3.
5
Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients?大剂量皮质类固醇能否改善住院 COVID-19 患者的结局?
J Med Virol. 2022 Jan;94(1):372-379. doi: 10.1002/jmv.27357. Epub 2021 Oct 8.
6
The potential impact of enhanced hygienic measures during the COVID-19 outbreak on hospital-acquired infections: A pragmatic study in neurological units.2019年冠状病毒病疫情期间强化卫生措施对医院获得性感染的潜在影响:神经科病房的一项实用研究
J Neurol Sci. 2020 Nov 15;418:117111. doi: 10.1016/j.jns.2020.117111. Epub 2020 Aug 29.
7
Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort.服务欠缺的城市内城区人群中 COVID-19 患者的特征和临床结局:单中心三级队列研究。
J Med Virol. 2021 Jan;93(1):416-423. doi: 10.1002/jmv.26252. Epub 2020 Jul 15.
8
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
9
Bloodstream infections in critically ill patients with COVID-19.COVID-19 重症患者血流感染。
Eur J Clin Invest. 2020 Oct;50(10):e13319. doi: 10.1111/eci.13319. Epub 2020 Aug 11.
10
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.早期 COVID-19 治疗试验:与住院时间、死亡率和相关费用的关系。
Swiss Med Wkly. 2020 Dec 31;150:w20446. doi: 10.4414/smw.2020.20446. eCollection 2020 Dec 14.

引用本文的文献

1
Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility.斯洛伐克一家癌症医疗机构的员工接种第三剂BNT162b2后的体液免疫反应。
Biomed Rep. 2025 May 20;23(1):120. doi: 10.3892/br.2025.1998. eCollection 2025 Jul.
2
Catheter-associated urinary tract infections in the intensive care unit during and after the COVID- 19 pandemic.新型冠状病毒肺炎大流行期间及之后重症监护病房的导尿管相关尿路感染
BMC Infect Dis. 2025 Apr 24;25(1):595. doi: 10.1186/s12879-025-10996-2.
3
Analysis of Healthcare-associated Infections before and during the COVID-19 pandemic in a Colombian hospital.哥伦比亚一家医院在新冠疫情之前及期间的医疗相关感染分析
Rev Cuid. 2024 May 30;15(1):e3624. doi: 10.15649/cuidarte.3624. eCollection 2024 Jan-Apr.
4
Comparative Evaluation of Effectiveness of Standard of Care Alone and in Combination With Homoeopathic Treatment in COVID-19-Related Rhino-Orbito-Cerebral Mucormycosis (ROCM): Protocol for a Single Blind, Randomized Controlled Trial.标准治疗单独使用及联合顺势疗法治疗新型冠状病毒肺炎相关鼻眶脑毛霉菌病(ROCM)的有效性比较评估:一项单盲随机对照试验方案
JMIR Res Protoc. 2025 Mar 19;14:e57905. doi: 10.2196/57905.
5
The impact of COVID-19 pandemic on nosocomial infections in the cardiac care unit of a non-epidemic hospital in China.新型冠状病毒肺炎大流行对中国一家非疫情医院心脏监护病房医院感染的影响
Front Med (Lausanne). 2025 Jan 20;12:1483967. doi: 10.3389/fmed.2025.1483967. eCollection 2025.
6
Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.COVID-19 住院和重症患者并发念珠菌血症:系统评价和荟萃分析。
Mycoses. 2024 Oct;67(10):e13798. doi: 10.1111/myc.13798.
7
Device associated healthcare associated infection (DA-HAI): a detailed analysis of risk factors and outcomes in a university hospital in Rome, Italy.与设备相关的医疗保健相关感染(DA-HAI):对意大利罗马一家大学医院的危险因素和结果的详细分析。
Infect Prev Pract. 2024 Aug 18;6(4):100391. doi: 10.1016/j.infpip.2024.100391. eCollection 2024 Dec.
8
Risk of central line-associated bloodstream infections during COVID-19 pandemic in intensive care patients in a tertiary care centre in Saudi Arabia.沙特阿拉伯一家三级护理中心重症监护患者在 COVID-19 大流行期间发生中心静脉导管相关血流感染的风险。
Epidemiol Infect. 2024 Jun 3;152:e95. doi: 10.1017/S0950268824000736.
9
Impact of Povidone Application to Nares in Addition to Chlorhexidine Bath in Critically Ill Patients on Nosocomial Bacteremia and Central Line Blood Stream Infection.在重症患者中,除洗必泰浴外,在鼻孔应用聚维酮对医院获得性菌血症和中心静脉导管血流感染的影响。
J Clin Med. 2024 Apr 30;13(9):2647. doi: 10.3390/jcm13092647.
10
Development and validation of machine learning-based models for predicting healthcare-associated bacterial/fungal infections among COVID-19 inpatients: a retrospective cohort study.基于机器学习的模型用于预测COVID-19住院患者医疗相关细菌/真菌感染的开发与验证:一项回顾性队列研究
Antimicrob Resist Infect Control. 2024 Apr 14;13(1):42. doi: 10.1186/s13756-024-01392-7.

本文引用的文献

1
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.抗白细胞介素 6 受体托珠单抗在 2019 冠状病毒病重症和危重症患者中的安全性和有效性:一项对比分析。
J Infect. 2020 Oct;81(4):e11-e17. doi: 10.1016/j.jinf.2020.07.008. Epub 2020 Jul 8.
2
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
3
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.托珠单抗治疗 SARS-CoV-2 肺炎的同情用药。
Clin Infect Dis. 2020 Dec 15;71(12):3168-3173. doi: 10.1093/cid/ciaa812.
4
Short-Term Dexamethasone in Sars-CoV-2 Patients.新冠病毒患者的短期地塞米松治疗
R I Med J (2013). 2020 Jun 19;103(6):39-43.
5
Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.意大利米兰托珠单抗超适应证治疗严重急性呼吸综合征冠状病毒 2 型肺炎。
Eur J Intern Med. 2020 Jun;76:36-42. doi: 10.1016/j.ejim.2020.05.011. Epub 2020 May 21.
6
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.羟氯喹治疗主要为轻症和中症的 2019 冠状病毒病患者:开放标签、随机对照试验。
BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849.
7
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
8
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
9
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).氯喹和羟氯喹在冠状病毒病-19(COVID-19)中的预防作用的系统评价。
Int J Rheum Dis. 2020 May;23(5):613-619. doi: 10.1111/1756-185X.13842. Epub 2020 Apr 27.
10
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.